Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia.

S100B is a calcium-binding protein secreted in central nervous system from astrocytes and other glia cells. High blood S100B levels have been linked to brain damage and psychiatric disorders. S100B levels have been reported to be higher in schizophrenics than healthy controls. To quantify the relati...

Full description

Saved in:
Bibliographic Details
Main Authors: Katina Aleksovska, Emanuele Leoncini, Stefano Bonassi, Alfredo Cesario, Stefania Boccia, Alessandra Frustaci
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0106342&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849728284660596736
author Katina Aleksovska
Emanuele Leoncini
Stefano Bonassi
Alfredo Cesario
Stefania Boccia
Alessandra Frustaci
author_facet Katina Aleksovska
Emanuele Leoncini
Stefano Bonassi
Alfredo Cesario
Stefania Boccia
Alessandra Frustaci
author_sort Katina Aleksovska
collection DOAJ
description S100B is a calcium-binding protein secreted in central nervous system from astrocytes and other glia cells. High blood S100B levels have been linked to brain damage and psychiatric disorders. S100B levels have been reported to be higher in schizophrenics than healthy controls. To quantify the relationship between S100B blood levels and schizophrenia a systematic literature review of case-control studies published on this topic within July 3rd 2014 was carried out using three bibliographic databases: Medline, Scopus and Web of Science. Studies reporting mean and standard deviation of S100B blood levels both in cases and controls were included in the meta-analysis. The meta-Mean Ratio (mMR) of S100B blood levels in cases compared to controls was used as a measure of effect along with its 95% Confidence Intervals (CI). 20 studies were included totaling for 994 cases and 785 controls. Schizophrenia patients showed 76% higher S100B blood levels than controls with mMR = 1.76 95% CI: 1.44-2.15. No difference could be found between drug-free patients with mMR = 1.84 95%CI: 1.24-2.74 and patients on antipsychotic medication with mMR = 1.75 95% CI: 1.41-2.16). Similarly, ethnicity and stage of disease didn't affect results. Although S100B could be regarded as a possible biomarker of schizophrenia, limitations should be accounted when interpreting results, especially because of the high heterogeneity that remained >70%, even after carrying out subgroups analyses. These results point out that approaches based on traditional categorical diagnoses may be too restrictive and new approaches based on the characterization of new complex phenotypes should be considered.
format Article
id doaj-art-06200eaab4d8493f9f8ab0d189b7b13d
institution DOAJ
issn 1932-6203
language English
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-06200eaab4d8493f9f8ab0d189b7b13d2025-08-20T03:09:35ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0199e10634210.1371/journal.pone.0106342Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia.Katina AleksovskaEmanuele LeonciniStefano BonassiAlfredo CesarioStefania BocciaAlessandra FrustaciS100B is a calcium-binding protein secreted in central nervous system from astrocytes and other glia cells. High blood S100B levels have been linked to brain damage and psychiatric disorders. S100B levels have been reported to be higher in schizophrenics than healthy controls. To quantify the relationship between S100B blood levels and schizophrenia a systematic literature review of case-control studies published on this topic within July 3rd 2014 was carried out using three bibliographic databases: Medline, Scopus and Web of Science. Studies reporting mean and standard deviation of S100B blood levels both in cases and controls were included in the meta-analysis. The meta-Mean Ratio (mMR) of S100B blood levels in cases compared to controls was used as a measure of effect along with its 95% Confidence Intervals (CI). 20 studies were included totaling for 994 cases and 785 controls. Schizophrenia patients showed 76% higher S100B blood levels than controls with mMR = 1.76 95% CI: 1.44-2.15. No difference could be found between drug-free patients with mMR = 1.84 95%CI: 1.24-2.74 and patients on antipsychotic medication with mMR = 1.75 95% CI: 1.41-2.16). Similarly, ethnicity and stage of disease didn't affect results. Although S100B could be regarded as a possible biomarker of schizophrenia, limitations should be accounted when interpreting results, especially because of the high heterogeneity that remained >70%, even after carrying out subgroups analyses. These results point out that approaches based on traditional categorical diagnoses may be too restrictive and new approaches based on the characterization of new complex phenotypes should be considered.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0106342&type=printable
spellingShingle Katina Aleksovska
Emanuele Leoncini
Stefano Bonassi
Alfredo Cesario
Stefania Boccia
Alessandra Frustaci
Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia.
PLoS ONE
title Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia.
title_full Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia.
title_fullStr Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia.
title_full_unstemmed Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia.
title_short Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia.
title_sort systematic review and meta analysis of circulating s100b blood levels in schizophrenia
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0106342&type=printable
work_keys_str_mv AT katinaaleksovska systematicreviewandmetaanalysisofcirculatings100bbloodlevelsinschizophrenia
AT emanueleleoncini systematicreviewandmetaanalysisofcirculatings100bbloodlevelsinschizophrenia
AT stefanobonassi systematicreviewandmetaanalysisofcirculatings100bbloodlevelsinschizophrenia
AT alfredocesario systematicreviewandmetaanalysisofcirculatings100bbloodlevelsinschizophrenia
AT stefaniaboccia systematicreviewandmetaanalysisofcirculatings100bbloodlevelsinschizophrenia
AT alessandrafrustaci systematicreviewandmetaanalysisofcirculatings100bbloodlevelsinschizophrenia